Topical Roflumilast Rewrites the Safety Story by Route
Topical roflumilast shows how route of administration can rewrite a PDE4 inhibitor's safety profile, concentrating action in skin rather than circulation.
Topic
Roflumilast
Topic
Roflumilast
Arcutis presents ZORYVE cream data in infant eczema, details thin
Arcutis Biotherapeutics has presented new ZORYVE cream data in infants with eczema, per Investing.com Canada. The report carried…
Roflumilast Eases Sexual Difficulties in Genital Psoriasis
Roflumilast improved sexual difficulties in psoriasis patients with genital involvement, adding to the topical PDE4 inhibitor's p…
Arcutis Taps Simone Biles for New Zoryve Awareness Campaign
Arcutis has launched a new awareness campaign for Zoryve fronted by Olympic gymnast Simone Biles, aiming to shorten the path from…
Roflumilast 0.05% Cream Shows Early AD Clearance in Infants
Roflumilast cream 0.05% shows early atopic dermatitis clearance in infants, per Contemporary Pediatrics — a steroid-free PDE4 sig…
Roflumilast 0.05% Cream Clears Atopic Dermatitis Early in Infants
A Contemporary Pediatrics report signals early atopic dermatitis clearance in infants treated with once-daily roflumilast cream 0…